Nuclera has expanded its Series C funding round to USD $87 million following a new USD $12 million extension led by Elevage ...

The funding will support further development of eProtein Discovery to enable full-format antibody expression, purification, ...

Cambridge biotech Nuclera has boosted its Series C round to $87 million after securing a further $12m from a range of backers ...

Expanding eProtein Discovery with antibody-specific capabilities represents a strategic step as Nuclera moves into AI-enabled ...

Nuclera’s eProtein Discovery system, which accelerates drug discovery by providing rapid, easy access to functional proteins, ...

Oncologists have achieved some immune system responses in patients with pancreatic cancers using various combinations of ...

Eleven patients with refractory autoimmune hemolytic anemia (AIHA) were all brought into drug-free remission with CAR T-cell ...

Guanidine is an organic compound primarily used as a denaturing reagent to disrupt the structures of proteins and nucleic ...

Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer and begins in the cells lining the ...

Following the installation of eProtein Discovery at leading academic institutes across the UK and Europe 1, the expansion ...